OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ENE56

Centrum Medyczne Enel Med SA

Healthcare Facilities & ServicesVerified

The company's capital structure is characterized by a debt-to-equity ratio of 1.84, indicating a significant reliance on debt financing. Its liquidity position is moderate, with a current ratio of 0.6, suggesting that the company may face challenges in meeting its short-term obligations. The company's return on equity is 6.94%, which is relatively low, and its return on assets is 2.02%, indicating that the company is not generating substantial returns on its asset base. In terms of profitability, the company's operating income is 23,809,000 PLN, and its net income is 12,892,000 PLN. The gross profit is 79,644,000 PLN, which is a significant portion of the total revenue of 854,268,000 PLN. However, the company's profitability metrics are below the industry median, suggesting that it may be underperforming compared to its peers. The company's revenue is primarily concentrated in a single segment, as disclosed in its financial statements. There is no significant geographic diversification, and the company's operations are primarily based in Poland. This concentration may expose the company to higher risks if there are any adverse changes in the local market. The company's growth trajectory is modest, with a current revenue of 854,268,000 PLN. The analyst estimate for the last actual revenue is 441,144,000 PLN, which is significantly lower than the reported revenue. This discrepancy may indicate potential issues with the accuracy of the financial reporting or the company's performance. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital to meet its obligations. The dilution potential is low, but the company's reliance on debt financing may increase its financial risk. Recent events, as disclosed in the financial statements, include a significant capital expenditure of -77,596,000 PLN. This indicates that the company is investing in its operations, which may be a positive sign for future growth. However, the negative value suggests that the company is spending more on capital expenditures than it is generating in cash flow.

30-day price · ENE+0.00 (+0.0%)
Low$18.50High$20.60Close$19.00As of13 May, 00:00 UTC
Profile
CompanyCentrum Medyczne Enel Med SA
TickerENE.WA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Centrum Medyczne Enel Med SA operates in the healthcare facilities and services industry, providing medical services and related healthcare solutions.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92.

The company's capital structure is characterized by a debt-to-equity ratio of 1.84, indicating a significant reliance on debt financing. Its liquidity position is moderate, with a current ratio of 0.6, suggesting that the company may face challenges in meeting its short-term obligations. The company's return on equity is 6.94%, which is relatively low, and its return on assets is 2.02%, indicating that the company is not generating substantial returns on its asset base. In terms of profitability, the company's operating income is 23,809,000 PLN, and its net income is 12,892,000 PLN. The gross profit is 79,644,000 PLN, which is a significant portion of the total revenue of 854,268,000 PLN. However, the company's profitability metrics are below the industry median, suggesting that it may be underperforming compared to its peers. The company's revenue is primarily concentrated in a single segment, as disclosed in its financial statements. There is no significant geographic diversification, and the company's operations are primarily based in Poland. This concentration may expose the company to higher risks if there are any adverse changes in the local market. The company's growth trajectory is modest, with a current revenue of 854,268,000 PLN. The analyst estimate for the last actual revenue is 441,144,000 PLN, which is significantly lower than the reported revenue. This discrepancy may indicate potential issues with the accuracy of the financial reporting or the company's performance. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to raise additional capital to meet its obligations. The dilution potential is low, but the company's reliance on debt financing may increase its financial risk. Recent events, as disclosed in the financial statements, include a significant capital expenditure of -77,596,000 PLN. This indicates that the company is investing in its operations, which may be a positive sign for future growth. However, the negative value suggests that the company is spending more on capital expenditures than it is generating in cash flow.
Key takeaways
  • The company has a high debt-to-equity ratio, indicating a significant reliance on debt financing.
  • The company's liquidity position is moderate, with a current ratio of 0.6.
  • The company's profitability metrics are below the industry median, suggesting underperformance.
  • The company's revenue is concentrated in a single segment, increasing its exposure to market risks.
  • The company's capital expenditure is negative, indicating significant investment in operations.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is uncertain due to its low profitability metrics and high debt-to-equity ratio.",
Financial snapshot
PeriodHA-latest
CurrencyPLN
Revenue$854.3M
Gross profit$79.6M
Operating income$23.8M
Net income$12.9M
R&D
SG&A
D&A
SBC
Operating cash flow$109.6M
CapEx-$77.6M
Free cash flow$16.9M
Total assets$638.8M
Total liabilities$453.0M
Total equity$185.8M
Cash & equivalents$33.7M
Long-term debt$341.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$185.8M
Net cash-$307.9M
Current ratio0.6
Debt/Equity1.8
ROA2.0%
ROE6.9%
Cash conversion8.5%
CapEx/Revenue-9.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricENEActivity
Op margin2.8%5.6% medp25 -4.2% · p75 12.6%below median
Net margin1.5%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin9.3%36.5% medp25 23.7% · p75 65.2%bottom quartile
CapEx / revenue-9.1%-4.9% medp25 -11.5% · p75 -2.0%below median
Debt / equity184.0%69.3% medp25 7.9% · p75 120.9%top quartile
Observations
IR observations
Last actual revenue441,144,000 PLN
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-13 01:08 UTC#73923697
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 21:03 UTCJob: 09cb4471